Primary Bacteremia Due To S. Aureus Indication Finds Minimal Cmte. Support
Executive Summary
An indication for primary bacteremia caused by Staphylococcus aureus received little support from members of FDA's Anti-Infective Drugs Advisory Committee at an Oct. 14 meeting
You may also be interested in...
Pfizer Zyvox Study Of Catheter-Related Infections May Lower Enrollment Goal
Pfizer may change its enrollment goal for a Zyvox study depending on FDA's modification of its 1999 guidance on catheter-related bloodstream infections (CRBSI)
Pfizer Zyvox Study Of Catheter-Related Infections May Lower Enrollment Goal
Pfizer may change its enrollment goal for a Zyvox study depending on FDA's modification of its 1999 guidance on catheter-related bloodstream infections (CRBSI)
FDA Moving Forward On Primary Bacteremia Indication
FDA will continue work on defining an indication for primary bacteremia due to Staph aureus (PBSA) after the agency found support for the claim from the Anti-Infective Drugs Advisory Committee